Daniël Pieter Christiaan van der Spek

Mr. Daniël Pieter Christiaan van der Spek

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2022 in European Journal of Internal Medicine
Verified
Journal Article
Open access
DSDaniël Pieter Christiaan van der Spek
Daniël Pieter Christiaan van der Spek
WKW.K. Katwaroe
W.K. Katwaroe
LKL.A. van Kleef
L.A. van Kleef
SBSylvia Merel Brakenhoff
Sylvia Merel Brakenhoff
RMR.A. de Man
R.A. de Man
MSM.J. Sonneveld
M.J. Sonneveld
The incidence of chronic hepatitis B (CHB) is declining due to successful implementation of vaccination programs and widespread use of antiviral therapy. We aimed to study time-trends in disease characteristics and comorbidities in newly referred CHB patients. We collected information on hepatitis B virus (HBV) related disease characteristics (including hepatitis B e-antigen (HBeAg) status, viremia, stage of liver fibrosis and indication for treatment and/or hepatocellular carcinoma (HCC) surveillance) and presence of comorbidities in all CHB patients referred to our center from 1980 through 2020. Patient characteristics were compared according to referral date (before 2000, between 2000 and 2010 and after 2010). We identified 1515 eligible patients. Patients referred after 2010 were older (36 versus 34 years, p < 0.001), more often non-Caucasian (82.3% versus 55.0%, p < 0.001) and more frequently HBeAg negative (81.5% versus 49.8%, p < 0.001) when compared to patients referred before 2000. Adjusted for ethnicity, sex and age, patients referred after 2010 were less likely to have significant fibrosis (adjusted odds ratio [aOR]:0.178, p < 0.001) or indication for antiviral therapy (aOR:0.342, p < 0.001) but were more likely to be affected by the metabolic syndrome (aOR:1.985, p = 0.013), hepatic steatosis (aOR:1.727, p < 0.001) and metabolic dysfunction associated fatty liver disease (MAFLD) (aOR:1.438, p = 0.013). The characteristics of the CHB populations are changing. Newly referred patients are older, have less active HBV related liver disease but are more likely to be co-affected by MAFLD. These findings provide guidance for adequate allocation of resources to cope with the changing characteristics of the CHB population. Foundation for Liver and Gastrointestinal Research Rotterdam, the Netherlands and Gilead Sciences.

11 September 2024 in Pain Practice
Verified
Journal Article
Open access
DSDaniël Pieter Christiaan van der Spek
Daniël Pieter Christiaan van der Spek
MDMaaike Dirckx
Maaike Dirckx
TMThomas J. P. Mangnus
Thomas J. P. Mangnus
SCSteven P. Cohen
Steven P. Cohen
FHFrank J. P. M. Huygen
Frank J. P. M. Huygen
Introduction: Complex regional pain syndrome (CRPS) is a clinical disorder that can develop following surgery or trauma. Based on the most prominent underlying pathophysiological mechanisms, CRPS can be classified into different subtypes, namely inflammatory, nociplastic/neuropathic, vasomotor, and motor. Depending on the subtype, personalized treatment can be applied. If conservative treatments are insufficient or ineffective, more invasive treatments may be recommended. This article provides an overview of the most recent insights into CRPS and discusses the most common invasive treatments.Methods: The literature regarding interventional treatments for CRPS has been systematically reviewed and summarized.Results: Bisphosphonates are effective in treating the inflammatory subtype, while ketamine can provide pain relief for the nociplastic/neuropathic subtype. Sympathetic blocks are effective in addressing vasomotor disturbances. For patients with refractory symptoms, neurostimulation is a viable option due to its multimechanistic properties for all subtypes. End‐of‐line motor disturbances may benefit from intrathecal baclofen.Conclusions: CRPS is a debilitating condition with an unpredictable course. The effectiveness of treatment varies from patient to patient. When conservative approaches prove insufficient, gradual progression to invasive treatments based on the underlying subtype is recommended.

11 October 2022 in Viruses
Verified
Journal Article
Open access
PDF file
WKWarshan K. Katwaroe
Warshan K. Katwaroe
SBSylvia Merel Brakenhoff
Sylvia Merel Brakenhoff
DSDaniël Pieter Christiaan van der Spek
Daniël Pieter Christiaan van der Spek
RKRobert J. de Knegt
Robert J. de Knegt
LKLaurens A. Van Kleef
Laurens A. Van Kleef
TGthe ICARUS Study Group
the ICARUS Study Group
Background and aims: Adherence to guidelines is associated with improved long-term outcomes in patients with chronic hepatitis B (CHB). We aimed to study the degree of adherence and determinants of non-adherence to management guidelines in a low endemic country. Methods: We reviewed the medical records of all CHB patients who visited our outpatient clinic in 2020. Adherence to guidelines was assessed based on predefined criteria based on the EASL guidance, and included the initiation of antiviral therapy when indicated, the optimal choice of antiviral therapy based on comorbidities, an assessment of HAV/HCV/HDV/HIV serostatus, renal function monitoring and enrolment in a HCC surveillance program if indicated. The adherence rates were compared across types of outpatient clinic (dedicated viral hepatitis clinic versus general hepatology clinic). Results: We enrolled 482 patients. Among the 276 patients with an indication for antiviral therapy, 268 (97.1%) received treatment. Among the patients with renal and/or bone disease, 26/29 (89.7%) received the optimal choice of antiviral agent. The assessment of HAV/HCV/HDV/HIV serostatus was performed in 86.1/91.7/94.4/78.4%. Among the 91 patients treated with tenofovir disoproxil, 57 (62.6%) underwent monitoring of renal function. Of the 241 patients with an indication for HCC surveillance, 212 (88.3%) were enrolled in a surveillance program. Clinics dedicated to viral hepatitis had superior adherence rates compared to general hepatology clinics (complete adherence rates 63.6% versus 37.2%, p < 0.001). Conclusions: Follow-up at a dedicated viral hepatitis clinic was associated with superior adherence to management guidelines.

17 August 2025 in Regional Anesthesia & Pain Medicine
Verified
Journal Article
Open access
DSDaniël Pieter Christiaan van der Spek
Daniël Pieter Christiaan van der Spek
JGJulian Ghantous
Julian Ghantous
THTjebbe Hagenaars
Tjebbe Hagenaars
MPMarieke A Paping
Marieke A Paping
FHFrank Jpm Huygen
Frank Jpm Huygen
MDMaaike Dirckx
Maaike Dirckx
Introduction: Amputation in patients with complex regional pain syndrome (CRPS) remains controversial, with variable outcomes in quality of life (QoL), disability, pain reduction, and complications. This study aims to evaluate long-term outcomes in CRPS patients who underwent amputation. Methods: We conducted a single-center retrospective observational study combined with a cross-sectional survey of all CRPS patients who underwent limb amputation between 2003 and 2023 at the Erasmus MC University Medical Center. Preamputation and short-term postamputation outcomes were extracted from medical records, with short-term pain scores reflecting measurements within the first year after amputation. Long-term outcomes, including QoL, disability, pain, and satisfaction, were assessed through patient-reported questionnaires. Subgroup analyses were performed based on the presence of a neurostimulator implant. Results: A total of 39 patients with a median CRPS Severity Score of 12 (IQR 11–13) were included. 34 patients (87%) completed the survey a median of 6.4 years (IQR 3.0–11.7) after amputation. The 36-Item Short Form Health Survey yielded mean physical and mental health summary scores of 45.4 (±26.1) and 67.7 (±22.3), respectively. The mean Pain Disability Index score was 29.3 (±15.1). Pain decreased by a mean of 3.54 points (95% CI: 2.46 to 4.62) at short-term follow-up (median 5 months, IQR 2–6) and 2.71 points (95% CI: 1.76 to 3.65) at long-term follow-up. Residual limb pain occurred in 77%, phantom limb pain in 85%, and CRPS recurrence in the stump in 10%. Overall, 94% of respondents were satisfied and would choose amputation again. Neurostimulator status did not influence measured outcomes. Conclusions: In this cohort of severe, therapy-resistant CRPS, amputation was associated with meaningful improvements in QoL, disability, and pain in carefully selected cases, although complications remained common. Amputation should, therefore, be reserved as a last-resort intervention, offered only in specialized multidisciplinary centers.

1 February 2026 in Journal of Pain Research
Verified
Journal Article
Open access
DSDaniël Pieter Christiaan van der Spek
Daniël Pieter Christiaan van der Spek
FHFrank Huygen
Frank Huygen
SHSanne Hoeks
Sanne Hoeks
PDPaul van Daele
Paul van Daele
MDMaaike Dirckx
Maaike Dirckx
Pamidronate is a nitrogen-containing bisphosphonate with immunomodulatory and anti-osteoclastic properties that has shown benefit in early-onset complex regional pain syndrome (CRPS), yet evidence in persistent CRPS remains limited. Given that chronicity may attenuate therapeutic response, this study evaluates the effectiveness and tolerability of intravenous pamidronate in CRPS patients managed in routine clinical practice. We conducted a single-center retrospective observational study, including all adult CRPS patients treated with pamidronate between 2014 and 2024 at our tertiary referral center. Data were collected from medical records at baseline, during treatment and at routine follow-up at approximately 1-, 3-, 6-, and 12-months post-treatment. The primary outcome was the pain trajectory, analyzed using a linear mixed-effects model. Responders were defined by a ≥2-point NRS reduction or subjective benefit when NRS data were unavailable. Of 110 eligible patients, 97 were included with a median age of 45 (IQR 32–54), and a median disease duration of 31 months (IQR 9–97). Baseline mean NRS was 7.95 (95% CI: 7.66 to 8.25), declining by 1.10 points (95% CI: −1.49 to −0.70; p<0.001) at 1 month and by 0.66 points (95% CI: −1.13 to −0.20; p<0.01) at 3 months. Responder rates were 34% and 22%, respectively. Treatment-related adverse events occurred in 91% of patients but led to discontinuation in only 6%. In patients with predominantly persistent CRPS, intravenous pamidronate was well tolerated and associated with a modest, short-term pain relief up to 3 months. No sustained analgesic benefit was evident at later timepoints.

28 November 2025 in The Journal of Pain
Verified
Journal Article
Closed access
DSDaniël Pieter Christiaan van der Spek
Daniël Pieter Christiaan van der Spek
JBJan van Den Brink
Jan van Den Brink
FHFrank J.P.M. Huygen
Frank J.P.M. Huygen
MDMaaike Dirckx
Maaike Dirckx